RxDoctor Payments Data

Paul Lee, MD

Interventional Cardiology · West Islip, NYNPI 1376522912

Payments from drug & device makers

$65,044in general payments, 2019–2025

Across 597 payments — averaging $108.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$22K
  • Medtronic$17K
  • Edwards Lifesciences$8K
  • Boston Scientific$5K
  • Medical Device Business Services, Inc.$4K
  • Abiomed$1K
  • plus $8K from 32 others

What the payments were for

  • Consulting fees$5,5008%
  • Speaking & faculty fees$9,00014%
  • Grants$550%
  • Travel & lodging$24,73038%
  • Food & beverage$25,76040%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$65,044 in reported general payments places this provider in the 75th percentile of 382 interventional cardiology providers in New York.

See all interventional cardiology providers in New York

Medicare billing

Part B allowed, 2024
$430,901
Medicare patients
983
Services billed
3,775

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban62$67,795
EntrestoSacubitril/Valsartan45$59,729
FarxigaDapagliflozin Propanediol39$50,205
JardianceEmpagliflozin40$41,940
XareltoRivaroxaban18$16,242
BrilintaTicagrelor14$12,753
Nebivolol Hcl31$2,551
Metoprolol Succinate157$2,179
Pitavastatin Calcium11$1,423
Rosuvastatin Calcium96$1,402
Atorvastatin Calcium169$1,317
Ezetimibe52$1,203
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide36$988
ClopidogrelClopidogrel Bisulfate67$810
Valsartan42$603

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$272$67,79562 claims
AstraZenecaFarxiga, Brilinta$45$62,95753 claims
NovartisEntresto$721$59,72945 claims
Boehringer IngelheimJardiance$208$41,94040 claims
Johnson & JohnsonXarelto$445$16,24218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 382 interventional cardiology providers in New York.

Other interventional cardiology in West Islip

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →